MicroRNA-222 is a potential target for developing blood-based diagnostic methods and treatment of malignant glioma

MicroRNA-222是开发基于血液的诊断方法和治疗恶性胶质瘤的潜在靶点

• 批准号: 22791355
• 负责人: UEDA Ryo
• 金额: $ 2.5万
• 依托单位: Keio University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2010
• 资助国家: 日本
• 起止时间: 2010 至 2011
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22791355/
• 关键词: 脳腫瘍学; microRNA; がん; 悪性脳腫瘍; 免疫抑制; バイオマーカー; エクソソーム

We previously reported that microRNA(miR)-222 over-expressed in cancer cells down-regulates ICAM-1, thereby reducing cancer cell susceptibility to cytotoxic T lymphocytes(CTLs). In this study, we found that miR-222 was up-regulated in some of human glioma tissues. Inhibition of miR-222 led to recovery of ICAM-1 expression in glioma cell lines, resulting in restoration of their susceptibility to CTL-mediated cytolysis. Thus, the increased miR-222 expression may contribute to glioma escape from the host immune surveillance. We then found that miR-222 could be detected by quantitative PCR in serum of glioma patients. Moreover, the elevated miR-222 expression was associated with disease progression and poor prognosis of the patients, suggesting possible development of new diagnostic methods for malignant characteristics of glioma and prognosis of the patients. Interestingly, miR-222 containing exosomes secreted from glioma cells may be uptaken by dendritic cells(DCs), and decreased ICAM-1 expression on DC, which is important for T cell activation. These results indicate that miR-222 may be a potential target for developing novel diagnostic and therapeutic methods for glioma patients.

我们以前报道过，在癌细胞中过表达的microRNA（miR）-222下调ICAM-1，从而降低癌细胞对细胞毒性T淋巴细胞（CTL）的易感性。本研究发现miR-222在部分人脑胶质瘤组织中表达上调。miR-222的抑制导致胶质瘤细胞系中ICAM-1表达的恢复，导致其对CTL介导的细胞溶解的敏感性恢复。因此，增加的miR-222表达可能有助于胶质瘤逃避宿主的免疫监视。结果发现，在胶质瘤患者血清中，可通过定量PCR检测到miR-222。此外，miR-222的高表达与患者的疾病进展和不良预后相关，提示可能开发新的胶质瘤恶性特征和患者预后的诊断方法。有趣的是，从胶质瘤细胞分泌的含有miR-222的外泌体可能被树突状细胞（DC）吸收，并降低DC上的ICAM-1表达，这对T细胞活化很重要。这些结果表明，miR-222可能是一个潜在的目标，为开发新的诊断和治疗方法的胶质瘤患者。

项目成果

グリオーマに発現するMicroRNA-222は新規診断法と治療法開発に有用である

神经胶质瘤中表达的 MicroRNA-222 可用于开发新的诊断和治疗方法

• 发表时间: 2010
• 作者: 植田良;萬倩;谷口智憲;岡田秀穂;小坂展慶;落谷孝広;河上裕
• 通讯作者: 河上裕

MicroRNA-222 is a potential target for developing blood-based diagnostic methods and treatment of malignant glioma.

MicroRNA-222是开发基于血液的诊断方法和治疗恶性神经胶质瘤的潜在靶标。

• 发表时间: 2010
• 作者: Ryo Ueda;Qian Li;Tomonori Yaguchi;Nobuyoshi Kosaka;Tomonobu Fujita;Hideho Okada;Takahiro Ochiya;Yutaka Kawakami
• 通讯作者: Yutaka Kawakami

MicroRNA-222 is a potential target for developing blood-based biomarker assay and treatment of malignant glioma.

MicroRNA-222 是开发基于血液的生物标志物检测和治疗恶性神经胶质瘤的潜在靶点。

• 发表时间: 2010
• 作者: Ryo Ueda;Li Qian;Tomonori Yaguchi;Nobuyoshi Kosaka;Tomonobu Fujita;Hideho Okada;Takahiro Ochiya;Yutaka Kawakami
• 通讯作者: Yutaka Kawakami

癌細胞由来エクソソームによる免疫系への作用とその臨床応用

癌细胞源性外泌体对免疫系统的影响及其临床应用

• 发表时间: 2010
• 期刊: 実験医学
• 作者: 植田良;LiQian;中村公子;谷口智憲;宮崎潤一郎;川村直;河上裕
• 通讯作者: 河上裕

実験医学

实验医学

• 发表时间: 2011
• 作者: 松田憲之;尾勝圭;田中啓二
• 通讯作者: 田中啓二